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Sub-Saharan Africa carries the greatest global HIV/AIDS burden. 
South Africa (SA), an epicentre for HIV/AIDS, has an estimated 
adult HIV prevalence of ~12.6%.[1] In 2016, an estimated 7.1 million 
South Africans were living with HIV, of whom 56% were accessing 
antiretroviral therapy (ART).[2] More than 95% of HIV-positive 
pregnant women were accessing treatment to prevent mother-to-
child transmission of HIV.[2] 
Efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor 
(NNRTI), has formed part of the SA national first-line ART 
since 2004. Subsequently, with the introduction of a fixed-dose 
combination (FDC) formulation with tenofovir and emtricitabine, 
EFV became the favoured first-line NNRTI in 2015. A change in SA 
government policy necessitated the treatment programme change. [3] 
Importantly, HIV-positive pregnant women were prioritised for 
immediate ART initiation with EFV-based first-line therapy when 
the World Health Organization deemed it safe for use in pregnancy 
after initial concerns.[4] As a result, all HIV-positive pregnant or 
breastfeeding women are currently commenced on lifelong ART with 
EFV as part of the first-line regimen in many programmes, regardless 
of CD4 count or duration of gestation, especially in low- and middle-
income countries (LMICs).[5]
Documented adverse effects of EFV include most notably 
the neuropsychiatric effects of insomnia, depression and EFV 
encephalopathy.[6] These side-effects are thought to be dose-
related and can be attributed to the ‘slow-metaboliser’ phenotypes 
where cytochrome P450 2B6 (CYP2B6) genotypic polymorphism 
combinations result in elevated plasma EFV concentrations in 
HIV-infected black African adults and children.[7] There are no data 
to suggest that similar mechanisms are linked to its hepatotoxic 
potential.
Alhough hepatotoxicity is well described in the NNRTI class of 
antiretrovirals, it is nevirapine (NVP) as opposed to EFV that has 
the higher reported incidence of drug-induced liver injury (DILI). 
This well-described hypersensitivity reaction is marked by rash, 
eosinophilia and hepatitis (a drug reaction with eosinophilia and 
systemic symptoms (DRESS) syndrome phenomenon) and typically 
This open-access article is distributed under 
Creative Commons licence CC-BY-NC 4.0.
A natural history of efavirenz drug-induced liver injury
D Maughan,1 MB ChB, FCP (SA), MMed (Med); M Sonderup,1 B Pharm, MB ChB, FCP (SA), MMed (Med), FRCP (Lond);  
N Gogela,1 MB ChB, FCP (SA), M Phil (Med); M Locketz,2 MB ChB, FCP Path (SA), MMed (Path); H Wainwright,2 MB ChB, FC Path (SA); 
M Setshedi,1 MB ChB, Cert Gastroenterol (SA), PhD; C W Spearman,1 MB ChB, FCP (SA), MMed (Med), PhD, FRCP (Lond)
1  Division of Hepatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town, 
South Africa
2  Department of Anatomical Pathology, Faculty of Health Sciences, University of Cape Town and National Health Laboratory Service, Cape Town, 
South Africa
Corresponding authors: D Maughan (deborah.maughan@uct.ac.za), M Sonderup (mark.sonderup@uct.ac.za)
Background. Efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor, has been a component of first-line antiretroviral therapy 
(ART) in the South African HIV/AIDS programme since 2004. It is extensively used in ART programmes in other low- and middle-income 
countries. The natural history of the previously recognised EFV drug-induced liver injury (DILI) is not known.
Objectives. To define and establish a causality assessment for EFV DILI and document its natural history by detailing a patient cohort. All 
relevant features characterising the patterns of clinical and histological injury, the duration of clinical and biochemical recovery and the 
associated mortality rate were documented. Factors associated with specific histological patterns of liver injury were analysed.
Methods. Patients were prospectively included after meeting causality and inclusion criteria for EFV DILI. Clinical, demographic and 
liver histological features (where possible) were documented from the time of presentation and throughout follow-up. Prednisone at 0.25 - 
0.5 mg/kg was initiated at the discretion of the treating hepatologist.
Results. Fifty patients were prospectively included in the analysis. The median age was 34 (interquartile range (IQR) 29 - 39) years, males 
being older than females (p=0.014). Most (92%) were female, and 86% were of black African ethnicity. The median duration of ART at 
presentation was 6 months, with half of the women having initiated ART during pregnancy, at a median gestation of 24 (IQR 11 - 36) weeks. 
The median CD4 nadir at ART treatment initiation was 517 cells/µL, with no significant difference in CD4 nadir between those who were 
pregnant and those who were not (p=0.6). The median RUCAM (Roussel Uclaf Causality Assessment Method) score was 7, and among the 
75% of patients who had liver biopsies, three histological patterns were identified: submassive necrosis (60%), nonspecific hepatitis (35%), 
and mixed cholestatic hepatitis (5%). On multivariate analysis, predictors for the development of submassive necrosis included younger 
age (<30 years; p=0.045), ART initiation in pregnancy (p=0.02), and a baseline CD4 count >350 cells/µL (p=0.018). For the nonspecific 
hepatitis group, pregnancy was also an associated factor (p=0.04). The mortality rate was 14%, with a median time from admission to 
death of 15 days. The median (IQR) time to initial hospital discharge was a lengthy 33 (24 - 52) days. Biochemical recovery was prolonged, 
necessitating a follow-up period of more than a year at an outpatient specialist clinic, with 86% of patients initiating a protease inhibitor-
based ART regimen successfully.
Conclusions. EFV DILI is a severe drug complication of ART with appreciable mortality and significant inpatient morbidity, requiring 
prolonged hospitalisation and follow-up.
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occurs early (within the first 2 months of taking NVP), is observed 
more commonly in women, and is associated with higher body mass 
index (BMI).[8]
Drug hepatotoxicity with EFV is recognised, but is reported 
to occur at a frequency far less than with NVP. No particular 
characteristics have been associated with EFV hepatotoxicity, and 
the natural history of EFV DILI is as yet not described. In SA, three 
distinct clinicopathological patterns of EFV DILI were defined in 
2016.[9] One histological pattern, submassive necrosis, was associated 
with significant morbidity and mortality. The biochemical, clinical 
and histological features of this novel injury indicated that it was a 
severe injury requiring prolonged hospitalisation, and predictors of 
risk included female gender, higher CD4 nadir at drug initiation, and 
younger age.[9]
There is very little information on EFV DILI in the literature. 
A few case reports describe strong causality with regard to suspected 
EFV DILI, with little documented on the natural history and clinical 
manifestations of the injury.[10-13]
Objectives
We prospectively documented patients with EFV DILI to evaluate 
and describe the natural history of this novel injury, including clinical 
and histological characteristics, management and outcomes.
Methods
We conducted an observational, prospective cohort study of patients 
presenting to the Division of Hepatology/Liver Clinic at Groote 
Schuur Hospital, Cape Town, SA, and identified as meeting causality 
criteria for EFV DILI.
Inclusion criteria for EFV DILI were: (i) a temporal relationship 
between drug exposure and clinical disease; (ii) exclusion of acute 
viral hepatitis (hepatitis A, B, C and E); (iii) antinuclear factor and/
or anti-smooth-muscle antibody ≤1:80 plus histological features not 
compatible with autoimmune hepatitis; (iv) radiological exclusion of 
biliary and vascular obstruction; (v) exclusion of alcohol/herbal toxins; 
and (vi) observing the effects of drug dechallenge and a histological 
injury pattern (if biopsy feasible) compatible with a DILI. For viral 
hepatitis specifically, hepatitis E was assessed by means of an in-house 
hepatitis E polymerase chain reaction (PCR) test rather than serology, 
given the low sensitivity and specificity of available commercial kits 
in our service.[14] Hepatitis A IgM, hepatitis B surface antigen and 
core IgM and hepatitis C antibody (Abbot ARCHITECT, USA) were 
screened to exclude acute hepatitis A, B and C. Additionally, the 
RUCAM (Roussel Uclaf Causality Assessment Method) causality 
model was used as a causality assessment tool to categorise the 
likelihood of EFV being causative.[15] The RUCAM scale involves a 
scoring system that categorises the suspicion of a DILI into ‘definite 
or highly probable’ (score >8), ‘probable’ (score 6 - 8), ‘possible’ (score 
3 - 5), ‘unlikely’ (score 1 - 2) and ‘excluded’ (score 0).
Prospectively, patients fulfilling causality for EFV DILI had 
relevant clinical and demographic data collected following informed 
and written consent. At the discretion of the treating hepatologist, 
and with sepsis excluded, patients were initiated on oral prednisone 
at 0.25 - 0.5 mg/kg, starting at a low dose and titrating according to 
response. Once biochemical normality or the patient’s baseline was 
achieved, progressive weaning of steroids occurred until complete 
discontinuation, at which time patients were discharged back to 
primary care.
The patients’ clinical course and biochemical recovery were 
documented up to at least 12 months after initial presentation. 
Follow-up after hospital discharge took place at the Liver Clinic, 
Groote Schuur Hospital. Recovery was defined as a return of the liver 
profile to normal or to the patient’s baseline before ART initiation, 
if known, in addition to complete resolution of initial clinical 
symptoms. The cumulative dose of immunosuppressive therapy was 
extracted from the electronic Medicines Management System.
As part of the standard of care in assessing causality and requirement 
for corticosteroid therapy (presence of immune-allergic pattern of 
injury with inflammation), liver biopsies (including trans-jugular 
biopsies, if clinically warranted) were performed unless uncorrectable 
coagulopathy or clinical risk precluded a safe procedure.
Histological patterns of EFV DILI are immune-allergic in nature, 
and in standardising EFV DILI histological patterns of injury 
reporting, the following three patterns were noted:[9]
Submassive necrosis. Morphologically zonal or panzonal necrosis 
with inflammatory cell infiltrates composed of lymphocytes, plasma 
cells, and conspicuous eosinophils.
Nonspecific hepatitis with portal and/or lobular inflammation 
particularly in zone 3 with/without cholate stasis in zone 1, with 
inflammatory cells including lymphocytes and eosinophils.
Mixed cholestatic hepatitis. A combination of portal tract 
inflammation/interface hepatitis with inflammatory cells, including 
lymphocytes and eosinophils with marked zone 3 bilirubinostasis and 
a ductular reaction.
Eosinophils were anticipated in all three histological patterns of 
injury as part of the inflammatory cell infiltrate.[9]
Ethics approval was obtained from the Faculty of Health Sciences 
Human Research Ethics Committee at the University of Cape Town 
(ref. no. 593/2018).
Statistical analysis
Statistical analyses were performed using Stata release 15, 2017 
(StataCorp. USA). Demographic and clinical characteristics were 
summarised with descriptive statistics. Categorical variables were 
presented as frequencies and percentages. Means and standard 
deviations were used for normal or parametric distributed data and 
medians with interquartile ranges (IQRs) for non-parametric data. 
Continuous variables were compared using either Student’s t-test 
(parametric) or the Wilcoxon rank-sum test (non-parametric). For 
laboratory data that included more than two groups, the Kruskal-
Wallis and Mann-Whitney U-test/Wilcoxon rank-sum test were 
utilised for non-parametric data. Logistic regression multivariate 
analysis was performed on factors found significant on univariate 
analysis to identify potential factors associated with the two dominant 
histological patterns of liver injury (the third pattern was too few in 
numbers to analyse meaningfully). All regression estimates were 
presented with 95% confidence intervals, and all p-values were 
considered significant at p<0.05.
Results
Fifty patients met the causality criteria for EFV DILI and were 
prospectively included in the analysis. An additional 7 patients were 
evaluated but were not included. Of these 7 patients, 2 died shortly 
after admission and were unable to provide consent, 2 had probable 
isoniazid (INH) DILI, 2 were diagnosed with autoimmune hepatitis, 
and 1, who was on EFV and then switched to NVP, probably had 
NVP DILI. The baseline demographic characteristics of the patients 
are listed in Table 1. Notably, most patients (n=46; 92%) were female 
and most were of black African ethnicity (n=43; 86%). The median 
(IQR) age was 34 (29 - 39) years, males being older than females 
(p=0.014) (although there were very few men, n=4). The median 
(IQR) BMI was 25 (22 - 23), with a range from normal to obese BMI.
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The median (IQR) duration of ART at the time of presentation was 
6 (5 - 10) months. Half of the women had initiated ART during 
pregnancy, at a median (IQR) gestation of 24 (11 - 36) weeks. Where 
ART was initiated in pregnancy, patients presented a median (IQR) of 
3 (2 - 6) months after delivery. Notably, the median CD4 nadir at ART 
treatment initiation was 517 cells/µL, with no significant difference 
(p=0.6) in CD4 nadir between patients who were pregnant and those 
who were not.
With regard to reported alcohol use, 28% drank alcohol, although 
typically this did not exceed 4 units of alcohol per week. Autoimmune 
serology was positive in 9 patients, with 1 patient antinuclear 
antibody- and 8 anti-smooth-muscle antibody-positive. The auto-
antibody titres were all low at ≤1:100. Significantly, liver biopsies 
were not compatible with an autoimmune hepatitis pattern of injury 
in these patients. Two patients were co-infected with hepatitis B, both 
hepatitis B e-antigen-negative with an undetectable hepatitis B DNA 
viral load at presentation. Hepatitis C antibody was not detected in 
any patient. No patients were hepatitis E virus PCR-positive.
Table 2 notes the median (IQR) RUCAM score of 7 (6 - 9), 
denoting EFV DILI in the probable category. Of the 50 patients, 
6 (12%) had received INH preventive therapy and 3 previous 
tuberculosis (TB) therapy, while 1 patient had previously been on 
co-trimoxazole prophylaxis. The clinical course, histological findings 
and temporal relationship with drug use and clinical onset were 
not compatible with INH- or co-trimoxazole-induced liver injuries. 
Given the severity of the injury, EFV rechallenge was not attempted 
in any of the patients. The RUCAM score therefore did not reflect 
the three potential additional points from a failed EFV rechallenge.
The median (IQR) duration of admission or time to initial 
discharge from hospital was 33 (24 - 52) days. The median (IQR) time 
Table 1. Baseline demographic data (N=50 patients)
Parameters p-value*
Age (years), median (IQR) 34 (29 - 39)
Females 34 (29 - 38)




Black African 43 (86)
Mixed ancestry 7 (14)
BMI (kg/m2), median (IQR) 25 (22 - 33)
ART initiated in pregnancy, n (%) 23 (46)
Months post partum at presentation, median (IQR) 3 (2 - 6)
CD4 count† (cells/µL), median (IQR) 517 (348 - 722)
Pregnant (n=23) 553 (424 - 792)
Not pregnant (n=27)‡ 424 (301 - 658) 0.6
Female 539 (354 - 780) 0.07
Male 152 (109 - 289)
Duration of ART (months), median (IQR) 6 (5 - 10)
Alcohol consumption,§ n (%) 14 (28)
HBsAg-positive, n (%) 2 (4)
HBV core IgM-positive, n/N 0/2
HBV viral load <20 IU/mL, n/N 2/2
HCV antibody-positive, n (%) 0
HEV IgM antibody-positive, n (%) 1 (2)
HEV PCR-positive, n/N 0/1
Autoimmune serology, n (%)
Antinuclear antibody-positive 1 (2)
Anti-smooth-muscle antibody-positive 8 (16)
Titre  ≤1:100 8 (16)
Anti-liver kidney microsomal type 1 antibody-positive 0
Medication use, n (%)
Co-trimoxazole 1 (2)
INH prophylaxis 6 (12)




IQR = interquartile range; BMI = body mass index; ART = antiretroviral therapy; HBsAg = hepatitis B surface antigen; HBV = hepatitis B; HCV = hepatitis C; HEV = hepatitis E;  
PCR = polymerase chain reaction; INH = isoniazid; TB = tuberculosis; RIF = rifampicin; PZA = pyrazinamide; EMB = ethambutol.
*p-values for univariate analysis.
†CD4 nadir.
‡Included 4 males.
§Defined as consuming any alcohol >1 unit per week.
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to biochemical recovery was 574 (239 - 728) days. Fig. 1 graphically 
notes the trends in median liver profile parameters over the initial 
12-month period following presentation. Jaundice resolved between 
months 3 and 6, with alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) time to normalisation extending well beyond 
6 months.
Among the 74% of patients who had liver biopsies (n=37), three 
histological patterns were identified: submassive necrosis (n=22; 
60%), nonspecific hepatitis (n=13; 35%) and mixed cholestatic 
hepatitis (n=2; 5%). All three of these patterns were associated with 
grade 4 ALT elevation (using the modified AIDS Clinical Trial Group 
grading).[16]
Despite the immune-allergic nature of the liver histological pattern, 
no patients had any skin rash associated with EFV DILI.
The most severe injury, clinically, biochemically and histologically, 
was submassive necrosis. Table 3 sets out these patterns of liver 
profiles at presentation. Bilirubin was significantly more elevated 
with this pattern of injury compared with the nonspecific hepatitis 
or mixed cholestatic hepatitis patterns (p=0.012). This occurred in 
the absence of a significant difference in ALT presentation in the 
three patterns (713, 927 and 510 U/L, respectively; p=0.55). Synthetic 
dysfunction at presentation, as measured by the international 
normalised ratio, was significantly greater in the submassive necrosis 
group compared with the other two pattern of injury groups (1.72, 
1.19 and 1.13, respectively; p<0.0001).
On univariate analysis, the following parameters were significantly 
associated with the two dominant histological patterns, submassive 
necrosis and nonspecific hepatitis: age <30 years (p=0.008 and 
p=0.080, respectively); CD4 nadir >350 cells/µL (p=0.001 and p=0.05, 
respectively); pregnant when ART initiated (p=0.001 and p=0.06, 
respectively); alcohol use (p=0.1 and p=0.015, respectively), and 
BMI >25 kg/m2 (p=0.02 and p=0.1, respectively). Table 4 reflects 
the multivariate logistic regression analysis of significant parameters 
on univariate analysis. Factors significantly associated with the 
development of submassive necrosis included younger age (<30 years; 
p=0.045), ART initiation in pregnancy (p=0.02), and a baseline CD4 
count >350 cells/µL (p=0.02). For the nonspecific hepatitis group, 
only pregnancy was an associated factor (p=0.03).
Most patients (n=42; 84%) were treated with corticosteroids. The 
median (IQR) duration of treatment with prednisone was 11 (8 - 16) 
months, with a cumulative prednisone dose of 3 198 (1 898 - 4 670) 
mg. All patients were successfully weaned from corticosteroids. Ten 
patients had episodes of in-hospital sepsis, of whom 3 were culture-
positive and 7 were culture-negative when a presumptive diagnosis 
based on clinical criteria was made. Steroid-induced diabetes mellitus 
occurred in 10% (n=5). During follow-up, 86% (n=37/43) were 
restarted successfully on protease inhibitor (PI)-based ART and 70% 
(n=30/43) were virologically suppressed at their last visit. No patients 
met clinical criteria for TB immune reconstitution inflammatory 
syndrome.
The mortality rate was 14% (n=7), all deaths occurring within the 
first 16 days after presentation. All deaths occurred in the patients 
who were not biopsied, as poor general clinical condition and 
coagulopathy precluded a safe procedure.
Discussion
We report the first study documenting the natural history of EFV 
DILI. Several insights have emerged that allow for better clinical 
understanding and therefore better patient management. A long 
latency period of 6 months from initiation of the EFV-based ART 
to presentation complicates the development of clear guidance for 
patients at risk, given that regular monitoring for the large number 
of patients in the national ART programme will be logistically 
challenging. Furthermore, unlike NVP DILI, there are no phenotypic 
features of a hypersensitivity or DRESS-type syndrome observed 
with the liver injury. This lack compounds the difficulty in detection 
Table 2. Clinical and follow-up characteristics (N=50 patients)
RUCAM score, median (IQR) 7 (6 - 9)
Clinical features, n (%)
Jaundice 47 (94)
Skin rash 0
EFV encephalopathy* 2 (4)
Outcome
Recovery, n (%) 37 (74)
Duration of admission (days), median (IQR) 33 (24 - 52)
Duration of outpatient follow-up, median (IQR) 574 (239 - 728)
Death, n (%) 7 (14)
Time to death (days), median (IQR) 15 (10 - 16)
Lost to follow-up, n (%) 6 (12)
Cumulative dose of prednisone (mg), median (IQR) 3 198 (1 898 - 4 670)
Duration of treatment with steroids (prednisone) (months), median (IQR) 11 (8 - 16)
Complications, n (%)
Sepsis (culture-positive) 3 (6)
Sepsis (culture-negative) 7 (14)
Steroid-induced DM 5 (10)




Unknown (lost to follow-up) 6
RUCAM = Roussel Uclaf Causality Assessment Method; EFV = efavirenz; DM = diabetes mellitus; ARV = antiretroviral; FTC = emtricitabine; TDF = tenofovir; RTV = ritonavir;  
ATV = atazanavir; LPV = lopinavir; 3TC = lamivudine; ABS = abacavir.
*EFV levels within toxic range (both patients >20 mg/L with therapeutic range 1 - 4 mg/L).
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of this drug injury. Jaundice is a universal presenting feature, and its 
presence should prompt clinicians to terminate therapy immediately 
and investigate for a possible DILI.
From an epidemiological perspective, our cohort probably 
represents typical HIV epidemiology in SA. Although we had few 
males, our female patients were significantly younger than the males, 
and the CD4 count at ART initiation in men was significantly lower 
than that in women. Both these demographic features are in keeping 
with known HIV/AIDS epidemiology in SA.[17] At lower CD4 counts, 
males tended to develop the mixed cholestatic-hepatitis pattern of 
injury. This is understandable, given our finding that a high baseline 
CD4 count is a clear risk factor for the submassive necrosis pattern 
of injury. Previous data inferred several predictors for this pattern of 
injury, including female gender, CD4 count and younger age.[9] Our 
study strengthened the findings of younger age and higher baseline 
CD4 count as associations with the more severe submassive necrosis 
injury pattern. The predominance of female gender in our prospective 
cohort is intriguing. Female gender has long been suggested as a 
risk factor for DILI.[18] However, this association was questioned 
in a study from Iceland, where female gender was not shown to be 
a risk factor for the development of DILI.[19] An association with 
initiation of the drug in pregnancy was demonstrated in our study, 
with almost half of our patients having started ART in pregnancy. 
These two parameters – gender and pregnancy – are compelling, 
but we are unable to establish for bias, given that HIV screening and 
treatment initiation is universal in our antenatal care programme. 
Pregnant women are therefore routinely screened and immediately 
linked to ART if HIV-positive, irrespective of CD4 count, as per 
policy. [5] Further data are required to understand the significance of 
the association of EFV DILI and pregnancy, as it may have important 
programmatic implications for antiretroviral programmes using EFV 
as first-line therapy in populations at risk. This may be a factor to 
be considered in recommending DILI surveillance in pregnant and 
postpartum women initiated on EFV in pregnancy, and in deciding 
whether EFV should be used as part of an ART regimen when 
initiated in pregnancy.
The morbidity and mortality associated with EFV DILI are 
substantial, characterised by the need for prolonged hospital 
admission (median 38 days) and a long follow-up period of more 
than a year. The mortality rate of 14% is significant and is in keeping 
with ‘Hy’s law’, denoting that jaundice and hepatocellular injury from 
a drug results in a mortality rate of at least 10%.[20] Death occurred 
within the first 2 weeks of admission in all patients who died, with 
most of these deaths occurring early. These patients had a severe 
coagulopathy that precluded safe biopsy, but were very likely to have 
had submassive necrosis as their pattern of injury.
Given the conspicuous mixed inflammatory cell immune-allergic 
pattern of injury on liver biopsy, initiation of 0.25 - 0.5 mg/kg of 
prednisone was standard of care, unless a contraindication precluded 
its immediate use. Weaning of corticosteroids with monitoring of 
liver enzymes commenced after 3 - 6 months and in most patients 
was completed at 12 months, after initiation of new PI-based ART. 
The use of corticosteroids in drug injuries is not standard of care, 
although they are often used, and data on their use are limited. There 
is a need for controlled trial data.[21]
Notably, positive autoimmune serology was present, albeit at low 
titres, in 9 patients. However,  the clinicopathological correlation 
for autoimmune hepatitis was weak. Firstly, anti-smooth-muscle 
antibodies can be nonspecifically detectable in the setting of significant 
liver necrosis, as in submassive necrosis.[22] Secondly, the histological 
Table 4. Multivariate logistic regression analysis of factors associated with histological patterns of efavirenz drug-induced liver injury
Factor Submassive necrosis, OR (95% CI); p-value Nonspecific hepatitis, OR (95% CI); p-value
Age <30 years* 1.5 (1.3 - 8.4); 0.045 1.04 (0.6 - 4.9); 0.7
Pregnancy† 7.1 (1.4 - 36.1); 0.018 0.2 (0.4 - 0.9); 0.03
CD4 >350 cells/µL‡ 5.4 (1.1 - 26.2); 0.02 4.4 (0.8 - 2.7); 0.2
Alcohol use 1.1 (0.8 - 1.2); 0.08 3.1 (0.8 - 12.9); 0.12
BMI§ 2.3 (0.6 - 9.9); 0.25 0.7 (0.2 - 2.7); 0.5
OR = odds ratio; CI = confidence interval; BMI = body mass index.
*Age at ART initiation.
†Pregnant when ART initiated.
‡CD4 nadir prior to ART initiation.
§Calculated at presentation.
Table 3. Laboratory parameters* of the three histological patterns of efavirenz-related drug-induced liver injury  
(N=33 liver biopsies performed)
Pattern of injury
Laboratory parameters





hepatitis (n=2), median p-value
Total bilirubin (µmol/L) 272 (210 - 317) 93 (63 - 276) 87 0.012
Conjugated bilirubin (µmol/L) 165 (117 - 228) 67 (16 - 156) 48 0.0054
ALT (U/L) 713 (470 - 1 445) 927 (389 - 1 174) 510 0.55
AST (U/L) 1 055 (571 - 1 966) 876 (374 - 1 403) 729 0.19
ALP (U/L) 296 (173 - 389) 170 (131 - 203) 271 0.0082
GGT (U/L) 229 (143 -  596) 264 (142 - 538) 615 0.7
INR 1.72 (1.5 - 2.28) 1.19 (1.1 - 1.4) 1.13 <0.0001
CD4 (cells/µL)† 553 (415 - 743) 538 (258 - 665) 205 0.033
ALT = alanine aminotransferase; AST = aspartate aminotransferase; ALP = alkaline phosphatase; GGT = gamma-glutamyl transferase; INR = international normalised ratio.
*Laboratory parameter (laboratory reference range). Data are expressed as medians and interquartile ranges.
†Nadir CD4 count at the initiation of antiretroviral therapy.
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findings were highly compatible with DILI 
and not autoimmune hepatitis, including 
an inflammatory cell infiltrate composed 
of mostly lymphocytes and eosinophils and 
scanty plasma cells. Lastly, the patients were 
all successfully weaned off steroid therapy in 
a relatively short space of time, an unlikely 
occurrence in autoimmune hepatitis. 
Biochemical stability was maintained off 
immunosuppression, and the majority of 
patients were successfully rechallenged on a 
PI-based regimen.
Further understanding of this liver injury, 
particularly the mechanisms at play in its 
aetiology, is crucial to identifying patients 
at risk. These mechanisms are likely to be 
multifactorial, including genetic, possibly 
related to CYP2B6 polymorphisms, as well 
as immunological, given the higher CD4 
counts in patients with the most aggressive 
histological and clinical patterns of injury. [23] 
What these factors are, almost certainly 
related to both HLA and non-HLA haplotype 
polymorphisms or variants, warrants further 
study. Also, with the number of patients 
accessing ART in a population with a possible 
predisposition to the ‘slow-metaboliser’ 
phenotype of CYP2B6 polymorphisms, 
genetic studies will potentially identify those 
patients at risk for EFV DILI in sub-Saharan 
Africa.[7] We are continuing further work in 
this respect.
Identification of this novel liver injury 
in 2016 did not lead to any significant 
programmatic changes in SA’s national ART 
guidelines. However, increased awareness of 
the injury was important in order to identify 
patients earlier and stop EFV appropriately. 
To this end, the Department of Health acted 
to educate clinicians about the novel aspects 
of EFV DILI and the importance of improved 
pharmacovigilance. Likewise, the drug 
regulator, the South African Health Products 
Regulatory Authority (SAHPRA), amended 
package inserts for EFV-containing ART. 
The hepatoxicity of EFV was not initially 
appreciated at the time of initial registration 
of the drug in the late 1990s. This failure 
to recognise hepatotoxicity as an issue with 
EFV emphasises the need for continued 
pharmacovigilance post drug marketing, 
especially in population groups not included 
in the initial drug trials. This phenomenon 
is not unique to EFV, but is of relevance to 
therapies seldom trialled in LMICs during 
initial registration studies.
In ART-naive patients, the recommended 
regimen in SA is now the tenofovir/
lamivudine/dolutegravir FDC. Although 
the absolute risk of neural tube defects is 
<0.05%, it is recommended that the risks 
and benefits of dolutegravir-based v. EFV-





































































Fig. 1. Trends in liver profile parameters over 1 year of follow-up: (A) total and conjugated bilirubin; 
(B)  ALT and AST; and (C) ALP, GGT and albumin.  (ALT = alanine aminotransferase; AST = 
aspartate aminotransferase; ALP = alkaline phosphatase; GGT = gamma-glutamyl transferase.) 
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of reproductive age or pregnant women.[24,25] EFV-based ART will 
therefore foreseeably still be prescribed in women of reproductive age 
or pregnant women, with the potential risks of severe EFV-induced 
liver injuries.[26]
Study limitations
The cohort size was relatively small and could be considered a study 
limitation; however, for a DILI, the numbers are significant. It was 
a single-centre study, although we are a regional and supra-regional 
referral centre. Even so, selection and referral bias is a consideration. 
The study was not significantly powered to be able to identify any 
significant predictors for death or prolonged time to recovery. 
However, given the fact that the natural history of EFV DILI has 
never been described, it provides important insight into the severity 
of the liver injury, in terms of both morbidity and mortality. We 
also did not calculate or infer an incidence of this DILI, given that 
although the number of people on ART in our referral region is 
known (in 2020, 206  591 people were on ART in the City of Cape 
Town metropolitan area – personal communication, Western Cape 
Province HIV Directorate), we lack precise data on numbers of 
people on EFV-based ART. Additionally, the significant movement 
of patients between provinces limits any potential estimation in this 
respect.
Conclusions
EFV DILI is a novel and severe injury associated with significant 
morbidity and mortality. Hospital admission and outpatient follow-
up are prolonged, with a need for adjunctive steroid therapy. 
CD4 counts >350 cells/µL, younger age and ART initiated in 
pregnancy were predictive for development of the severe submassive 
necrosis histological pattern of injury. EFV is likely still to be used, 
particularly in women of reproductive age, despite the introduction 
of dolutegravir as first-line therapy in the national ART programme 
since 2020. Furthermore, EFV is likely to remain in use in other 
LMICs for the foreseeable future. It is therefore vitally important 
to further elucidate the mechanisms underlying the injury, as well 
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